Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

• Sponsor: University of Alabama at Birmingham (Other)
• Overall Status: Completed
• CT.gov ID: NCT01307891
• Collaborator: Susan G. Komen Breast Cancer Foundation (Other), Daiichi Sankyo UK Ltd. (Other), Triple Negative Breast Cancer Foundation (Other)
• Enrollment: 64
• Locations: 10
• Arms: 2
• Duration (Months): 75
• Patients Per Site: 6.4
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women. Metastatic disease including metastatic breast cancer unfortunately remains incurable. One reason is due to the inability to develop specific therapies for specific cancer subsets.

The use of modern genomic techniques has significantly enhanced our recent understanding of breast cancer biology. Five distinct breast cancer subsets have been recognized, one of which is basal-like breast cancer. Basal-like breast cancer is typically estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER-2-Neu) negative. This is referred to as triple negative breast cancer or TBNC. TBNC represents a significant proportion of breast cancer patients (10-20%) and has a poor prognosis with no targeted approach to therapy as of yet.

Tigatuzumab is a humanized monoclonal antibody targeting a death receptor on the breast cancer cells. Previous studies have shown that combining antibodies with selected chemotherapy agents have induced tumor cell death. The hypothesis of this study is to use tigatuzumab and combine it with Abraxane to serve as a targeting agent in metastatic TBNC patients.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer; Triple Negative Breast Cancer; Stage IV Breast Cancer; Metastatic Breast Cancer	Drug: Abraxane alone; Drug: Abraxane + Tigatuzumab	Phase 2

Detailed Description

The study is an open-label randomized, multi-institutional, phase II clinical trial of Abraxane in combination with tigatuzumab or Abraxane as a single agent in patients with TNBC. Randomization (2:1) will be made from these two categories: TBNC patients with no prior chemotherapy for metastatic disease or TBNC patients with prior taxane (except Abraxane) therapy for metastatic disease. Patients randomized to Abraxane alone may be allowed to cross over to the combination of Abraxane + tigatuzumab if there is disease progression.

Study Design

• Study Type: Interventional
• Actual Enrollment: 64 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
• Study Start Date: Mar 1, 2011
• Actual Primary Completion Date: Jun 1, 2016
• Actual Study Completion Date: Jun 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Abraxane + Tigatuzumab Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.	Drug: Abraxane + Tigatuzumab; Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.; Other Names: Tigatuzumab, CS-1008
Experimental: Abraxane alone Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.	Drug: Abraxane alone; 100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).; Other Names: Abraxane, also ABI-007

Outcome Measures

Primary Outcome Measures

1. Objective Response Rate [Baseline to 6 months]

   Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI. Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression.

Secondary Outcome Measures

1. Number of Participants With Serious Adverse Events [Baseline to 6 months]

   Patients will be assessed throughout the study for Grade 4 or 5 toxicities utilizing the Common Toxicity Criteria for Adverse Events (CTCAE) v4.0.

2. Progression-free Survival [Baseline through 24 months]

   Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have pathologically documented Stage IV breast cancer. If blocks (paraffin-embedded tissue) from original diagnosis are available, they will be obtained to confirm the diagnosis and for correlative studies. Fifteen slides can be obtained from the block if the block is not available to be sent or released.

• Tumor must be HER-2-neu negative (defined as 0 or 1+ staining by immunohistochemistry or gene amplification ratio less than or equal to 2.0, by fluorescent in situ hybridization - FISH), estrogen and progesterone receptors negative (<10%).

• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded)

• Biopsy of a metastatic lesion is not required for protocol entry but all patients with reasonably accessible lesions (chest wall, breast, skin, subcutaneous, superficial lymph nodes, bones and liver metastases) must agree to biopsy.

1. Biopsies may be done with local anesthesia or intravenous conscious sedation, according to standard institutional guidelines.

2. If a biopsy requires general anesthesia, then it is only allowed if acquisition of tissue is necessary for clinical reasons and excess tissue that would otherwise have been discarded is then used for research purposes. If a biopsy requires general anesthesia, then a biopsy of that site for research purposes only, without a coexisting clinical indication is not allowed on this protocol.

3. Patients with reasonably accessible lesions as described above, who will not agree with the biopsy, will not be enrolled in the trial.

4. Patients with NO reasonably accessible lesions as described above can be enrolled in the trial.

Prior Therapy:

• There is no restriction as to the number of prior regimens for metastatic disease as long as patients have adequate performance status. Patients with no prior chemotherapy for metastatic disease and patients who have received prior therapy with taxanes for metastatic disease (taxol or taxotere) are eligible. Stratification will be used for randomization of these two categories (no prior chemotherapy for metastatic disease or prior taxane therapy for metastatic disease).

• Chemotherapy treatment prior to enrollment must be discontinued for at least 3 weeks prior to study entry.

• Patients must have completed radiation therapy at least 7 days prior to beginning protocol treatment.

• Patients must have recovered from all reversible toxicities related to prior therapy before beginning protocol treatment, and may not have any pre- existing treatment-related toxicities in excess of grade 1. Patients must have < grade 2 pre-existing peripheral neuropathy.

• Patients may receive bisphosphonates; however, if used, bone lesions may not be used for progression or response.

• At least 18 years of age (19 in Alabama).

• Life expectancy of greater than 12 weeks.

• ECOG performance status < or equal to 2.

• Patients must have normal organ and marrow function as defined below:

• Absolute neutrophil count: > or equal to 1,500/mcL,

• Hemoglobin: > or equal to 9 mg/dL,

• Platelets: > or equal to 100,000/mcL,

• Total bilirubin: < or equal to 1.5 X institutional upper limit of normal,

• AST(SGOT)/ALT(SGPT): < or equal to 2.5 X institutional upper limit of normal without liver metastases, OR < or equal to 5 X institutional upper limit of normal if documented liver metastases,

• Creatinine: < or equal to 2.0 mg/dL, OR calculated creatinine clearance greater than or equal to 50 mL/min (calculated by the Cockcroft and Gault method).

• Ability to understand and the willingness to sign a written informed consent document.

• Both men and women are eligible.

• Use of an effective means of contraception in subjects of child-bearing potential.

• Negative serum or urine beta-HCG pregnancy test at screening for patients with childbearing potential.

Exclusion Criteria:

• Patients may not be receiving any other investigational agents.

• Prior use of Abraxane for metastatic disease or in the adjuvant setting.

• Metastatic lesions identifiable only by PET.

• Patients may not be receiving concurrent chemotherapy for treatment of metastatic disease.

• Active brain metastases: evidence of progression < or equal to 3 months after local therapy (patients should be asymptomatic and off corticosteroids and anticonvulsants for at least 3 months prior to study entry).

• Patients with brain metastases must have at least one site of measurable disease outside of the central nervous system.

• Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, history of recent myocardial infarction, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant or lactating women are excluded. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated. These potential risks may also apply to other agents used in this study.

• A prior invasive malignant disease within five years except for skin cancer (squamous cell or basal cell carcinoma).

• Patients with known history of HIV or Hepatitis B because of potential for added toxicity from treatment regimen.

• Dementia or altered mental status that would prohibit the understanding of informed consent.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama at Birmingham (UAB)	Birmingham	Alabama	United States	35294
2	Georgetown University Medical Center	Washington, D.C.	District of Columbia	United States	20007
3	University of Chicago	Chicago	Illinois	United States	60637
4	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	United States	46202
5	Dana Farber Cancer Center Institute	Boston	Massachusetts	United States	02215
6	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	United States	48109
7	Memorial Sloan Kettering Cancer Center	New York	New York	United States	10065
8	University of North Carolina	Chapel Hill	North Carolina	United States	27599
9	Vanderbilt University	Nashville	Tennessee	United States	37232
10	Baylor University	Houston	Texas	United States	77030

Sponsors and Collaborators

• University of Alabama at Birmingham
• Susan G. Komen Breast Cancer Foundation
• Daiichi Sankyo UK Ltd.
• Triple Negative Breast Cancer Foundation

Investigators

• Principal Investigator: Andres Forero, M.D., University of Alabama at Birmingham

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Andres Forero, Professor, University of Alabama at Birmingham
• ClinicalTrials.gov Identifier: NCT01307891
• Other Study ID Numbers: F101004001 (UAB1028); TBCRC 019
• First Posted: Mar 3, 2011
• Last Update Posted: Oct 26, 2017
• Last Verified: Oct 1, 2017

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Andres Forero, Professor, University of Alabama at Birmingham: Triple negative breast cancer (TNBC); Metastatic breast cancer; Tigatuzumab (CS-1008); Abraxane (ABI-007); HER-2-neu negative; ER negative, PR negative
• Additional relevant MeSH terms: Breast Neoplasms; Triple Negative Breast Neoplasms; Albumin-Bound Paclitaxel; Paclitaxel

Study Results

Participant Flow

Arm/Group Title	Abraxane + Tigatuzumab	Abraxane Alone
Arm/Group Description	Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.	Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
Period Title: Overall Study
STARTED	42	22
COMPLETED	39	21
NOT COMPLETED	3	1

Baseline Characteristics

Arm/Group Title	Abraxane + Tigatuzumab	Abraxane Alone	Total
Arm/Group Description	Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.	Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).	Total of all reporting groups
Overall Participants	42	22	64
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	35 83.3%	18 81.8%	53 82.8%
>=65 years	7 16.7%	4 18.2%	11 17.2%
Sex: Female, Male (Count of Participants)
Female	42 100%	22 100%	64 100%
Male	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	1 2.4%	0 0%	1 1.6%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	14 33.3%	6 27.3%	20 31.3%
White	26 61.9%	16 72.7%	42 65.6%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	1 2.4%	0 0%	1 1.6%
Region of Enrollment (participants) [Number]
United States	42 100%	22 100%	64 100%

Outcome Measures

1. Primary Outcome

Title	Objective Response Rate
Description	Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI. Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression.
Time Frame	Baseline to 6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Abraxane + Tigatuzumab	Abraxane Alone
Arm/Group Description	Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.	Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
Measure Participants	39	21
Number (95% Confidence Interval) [percentage of patients]	28	38

2. Secondary Outcome

Title	Number of Participants With Serious Adverse Events
Description	Patients will be assessed throughout the study for Grade 4 or 5 toxicities utilizing the Common Toxicity Criteria for Adverse Events (CTCAE) v4.0.
Time Frame	Baseline to 6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Abraxane + Tigatuzumab	Abraxane Alone
Arm/Group Description	Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.	Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
Measure Participants	39	21
Count of Participants [Participants]	0 0%	0 0%

3. Secondary Outcome

Title	Progression-free Survival
Description	Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time Frame	Baseline through 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Abraxane + Tigatuzumab	Abraxane Alone
Arm/Group Description	Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.	Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
Measure Participants	39	21
Median (95% Confidence Interval) [months]	2.8	3.8

Adverse Events

Time Frame	Baseline to 24 months
Arm/Group Title	Abraxane + Tigatuzumab		Abraxane Alone
Arm/Group Description	Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks.		Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
All Cause Mortality
	Abraxane + Tigatuzumab		Abraxane Alone
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/39 (0%)		0/21 (0%)
Serious Adverse Events
	Abraxane + Tigatuzumab		Abraxane Alone
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	3/39 (7.7%)		3/21 (14.3%)
Blood and lymphatic system disorders
Neutropenia	1/39 (2.6%)	1	1/21 (4.8%)	1
Bilateral Pulmonary Thromboembolism	0/39 (0%)	0	1/21 (4.8%)	1
Infections and infestations
Fever	1/39 (2.6%)	39	1/21 (4.8%)	21
Empyema associated with a permanent thoracic catheter	1/39 (2.6%)	1	0/21 (0%)	0
Other (Not Including Serious) Adverse Events
	Abraxane + Tigatuzumab		Abraxane Alone
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	39/39 (100%)		21/21 (100%)
Blood and lymphatic system disorders
Anemia	16/39 (41%)	16	9/21 (42.9%)	9
Thrombocytopenia	3/39 (7.7%)	3	3/21 (14.3%)	3
Gastrointestinal disorders
Nausea	9/39 (23.1%)	9	5/21 (23.8%)	5
Anorexia	2/39 (5.1%)	2	4/21 (19%)	4
Diarrhea	4/39 (10.3%)	4	2/21 (9.5%)	2
Vomiting	4/39 (10.3%)	4	2/21 (9.5%)	2
General disorders
Fatigue	22/39 (56.4%)	22	11/21 (52.4%)	11
Alopecia	19/39 (48.7%)	19	11/21 (52.4%)	11
Nervous system disorders
Pheripheral Sensory Neuropathy	17/39 (43.6%)	17	10/21 (47.6%)	10

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.